{"url_path":"/sec/hcat/8-k/2026-07-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1636422/0001636422-26-000085-index.html","accession_number":"0001636422-26-000085","cik":"0001636422","ticker":"HCAT","issuer_name":"Health Catalyst, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1636422/0001636422-26-000085-index.html","primary_entity_key":"0001636422","primary_entity_name":"Health Catalyst, Inc."},"word_count":427,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nOn July 16, 2026, Health Catalyst, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The Company’s stockholders voted on four proposals at the Annual Meeting, each of which is described in greater detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on June 3, 2026. The number of shares of the Company's common stock entitled to vote at the Annual Meeting was 73,894,020. The number of shares of the Company’s common stock present or represented by valid proxy at the Annual Meeting was 54,417,854. The final voting results with respect to each such proposal are set forth below.\n\nProposal 1 – Election of Directors\n\nThe Company’s stockholders elected each of the two persons named below to serve as a Class I director of the Company to serve a three-year term expiring at the 2029 annual meeting of the stockholders or until their successors are duly elected and qualified, subject to their earlier resignation or removal. The results of such vote were as follows:\n\nDirector Name\n\nVotes For\n\nVotes Withheld\nBroker Non-Votes\n\nJustin Spencer41,161,528926,17212,330,154\n\nMathew Arens40,617,0621,470,63812,330,154\n\nProposal 2 – Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were as follows:\n\nVotes ForVotes AgainstAbstentions\n\n54,389,75526,0502,049\n\nProposal 3 – Advisory, Non-Binding Vote to Approve the Compensation of the Company’s Named Executive Officers\n\nThe stockholders approved the advisory, non-binding proposal to approve the compensation of the Company’s named executive officers. The results of such vote were as follows:\n\nVotes For\n\nVotes Against\nAbstentionsBroker Non-Votes\n\n40,369,051992,493726,15612,330,154\n\nProposal 4 – To Approve the Restatement of the Company's Amended and Restated Certificate of Incorporation to Phase Out the Classified Board Structure\n\nThe stockholders did not approve the proposal to restate the Company's Amended and Restated Certificate of Incorporation to phase out the classified board structure and provide that all directors elected at or after the Company's 2029 annual meeting of stockholders be elected on an annual basis. The results of such vote were as follows:\n\nVotes For\n\nVotes Against\nAbstentionsBroker Non-Votes\n\n41,751,707335,03495912,330,154\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nHEALTH CATALYST, INC.\n\nDate: July 17, 2026By:/s/ Jason Alger\n\nJason Alger\n\nChief Financial Officer"}